Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
zydus
10 tablet
Anastrozole
Keep in cold place
Delivering To:
Overview
Femistra tablet is a hormone therapy medication that is used to treat breast cancer in postmenopausal women. Anastrozole is the generic name of this medication, and it is a competitive non-steroidal aromatase inhibitor. This medication is strictly prescription-based. Femistra tablet can be used with other possible treatment options like radiation, surgery, etc, or can be taken alone. Advanced breast cancer that has spread to different areas of the body or within the breast can also be cured with the Femistra tablet.
Breast Cancer
Breast cancer
Most side effects of Femistra 1mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Constipation
Diarrhea
Weight gain, Heartburn Loss of appetite
Hair thinning
Tingling of hands and feet
Trouble sleeping
Dizziness
Chest pain
Swelling of hands
Yellowing of skin and eyes
Vision complications
Vaginal bleeding
The doctor prescribes this medicine; hence, it is advisable to follow the prescription. Femistra tablets are taken orally once a day, and they can be taken with or without food as advised by the doctor. Femistra tablet should be taken at the same time every day for maximum benefits. Contact your doctor or any healthcare provider in case of an overdose and seek medical attention immediately.
In many breast cancers, estrogen stimulates the uncontrollable growth of cancerous cells. Aromatase enzyme, present mainly in the adrenal glands can convert the androgens to estrogen, and this estrogen furthermore influences the cancerous cells. Thus, Femistra is a non-steroidal inhibitor that competitively binds to the aromatase enzyme and stops the production of estrogen. As a result, it inhibits the growth and spreading of the tumor cells.
Alcohol
unsafe
It is advisable not to consume alcohol while taking the Femistra tablet. It is suggested that to consult your doctor.
Pregnancy
consult your doctor
Do not take the Femistra tablet without consulting a doctor in case of pregnancy. Femistra tablet is considered not safe to use in case of pregnancy as it may harm the developing baby, according to research evidence.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding. Femistra tablet may cause toxicity to the developing baby as it may be transferred through the milk of the mother, so it's not considered safe to use Femistra tablet during breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine. Femistra Tablet can make you feel sleepy, affect your vision, alertness may be reduced. It is advised not to drive if these symptoms exist while taking Femistra Tablet.
Kidney
caution
Do not take the Femistra 1mg tablet without a doctor's consultation in case of kidney problems. Patients with severe kidney disease should use Femistra Tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular kidney test should be done to monitor the side effects of Femistra Tablet on the kidneys.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine. Patients with severe Liver disease should use Femistra Tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular liver test should be done to monitor the side effects of Femistra Tablet on the liver.
If you forget to take a dose of Femistra 1mg tablet consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.
Femistra is an anticancer tablet that is primarily used in the treatment of breast cancer.
Femistra tablets are taken orally once every day. However, it is advisable to follow the prescription given by the doctor.
It is advisable to store the Femistra tablets at a place below 30°C.
The doctor decides the course of treatment with Femistra depending on the stage of cancer, and the health of the patient.
Femistra 1mg tablet should only be used in post-menopausal women. However, contact the doctor immediately if you have not undergone menopause and have taken the medication.
As soon as you remember, take the missed dose of Femistra Tablet. Double dose should be avoided, and you must go back to the regular schedule.
Regular monitoring of organs like liver, kidney, lungs, heart, etc, and blood tests for cholesterol levels and bone mineral density are recommended.
No, before taking any other medicines, please discuss it with your doctor, as Femitra tablet can interact with tamoxifen or oestrogen-containing products and may reduce the effectiveness of the Femitra tablet.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
1.Miller, W. R., Bartlett, J., Brodie, A. M., et al. (2020). Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors, and do they matter? The Oncologist, 13(8), 829–837.
2.Anderson, W. F., Chatterjee, N., Ershler, W. B., et al. (2022). Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Research and Treatment, 76(1), 27–36.
3.Miller, W., Stuart, M., Sahmoud, T., et al. (2023). Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. British Journal of Cancer, 87(9), 950–955.
4.Yang, Y., Pan, W., Tang, X., Wu, S., & Sun, X. (2025). A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. Oncotarget, 8(29), 48362–48374.
5.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies, C., Godwin, J., et al. (2021). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet, 378(9793), 771–784.
6.Ingle, J. N., Suman, V. J., Ma, C. X., et al. (2025). Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids, 99(Pt A), 32–38.
7.Cairns, J., Ingle, J. N., Liu, M. C., et al. (2023). The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Research, 21(1), 47.
8.Tang, M. R., Wang, Y. X., Guo, S., Han, S. Y., & Wang, D. (2022). CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis, 17(9), 927
zydus
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.